CLXPF News and Press, Canadian Lynx Pete Ltd From 04/28/21

A clinical trial whose results were published last week has found that psilocybin may be used to treat depression. The phase 2 study was the first randomized trial that compared the effectiveness of commonly prescribed antidepressants with therapeutic doses of psilocybin. Its findings we...

A study conducted recently proposes that psychedelic-assisted therapy using MDMA to help treat PTSD is not as efficacious among individuals who have recently used psychiatric drugs commonly prescribed by doctors, known as selective serotonin re-uptake inhibitors. The research findings were...

Cybin (NEO: CYBN) (OTCQB: CLXPF) , a biotechnology company focused on progressing psychedelic therapeutics, has selected alcohol use disorder (“AUD”) as the initial target indication for its proprietary deuterated psychedelic tryptamine, CYB003. In the announcement, the compan...

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has selected Alcohol Use Disorder (“AUD”) as the initial targe...

In recent years, microdosing has become popular as a wellness trend, both in the United States as well as overseas in countries such as Australia. Microdosing involves consuming a low dose of a psychedelic drug to reduce anxiety and stress or boost performance. While there have been ...

Palm Beach, FL – April 21, 2021 – The psychedelics industry has entered the spotlight! The rapidly increasing acceptance of psychedelic treatments is creating a strong demand from therapists and patients for access to  the new products and therapies. Industry reports for ...

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has successfully demonstrated Proof of Concept for its deuterated tryptamine...

Cybin (NEO: CYBN) (OTCQB: CLXPF) , a biotechnology company focused on progressing psychedelic therapeutics, has announced the formation of its clinical advisory board. Additions to the board include Maurizio Fava, MD, psychiatrist-in-chief in the Department of Psychiatry at Massachusetts Ge...

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting at the Bloom Burton ...

This is Psychedellux – the week’s top business news in the psychedelics industry. Cybin said it was Starting the IND-enabling trials for CYB003 and CYB004 which is a step forward for Cybin to study these molecules. Our team hopes to produce a robust submission to the FDA t...